Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. 1990

H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
I. Medizinische Klinik, Christian-Albrechts-Universität, Kiel, Federal Republic of Germany.

1. The effect of chronic administration of oral contraceptive steroids (OCS) on the pharmacokinetics of the oral anticoagulant phenprocoumon was investigated in seven healthy females. 2. Plasma concentrations of phenprocoumon and the urinary recovery of unchanged as well as conjugated drug were measured following a single oral dose of 0.22 mg kg-1. A group of seven non-smoking, drug-free women matched for age and body weight served as controls. 3. Administration of OCS was associated with a significant increase in the clearance of phenprocoumon from 1.6 +/- 0.7 to 2.0 +/- 0.7 ml min-1 kg-1 (P less than 0.05). The urinary recovery of phenprocoumon glucuronide was significantly higher in OCS users (21.0 +/- 16 vs 14.0 +/- 10 (% of dose); P less than 0.05). No difference in plasma protein binding of phenprocoumon was observed, being 99.2 +/- 0.07 in both groups. 4. The accelerated glucuronidation of phenprocoumon in OCS users suggests the need for careful monitoring of the anticoagulatory response in these subjects, especially when the OCS are withdrawn.

UI MeSH Term Description Entries
D010644 Phenprocoumon Coumarin derivative that acts as a long acting oral anticoagulant. Phenprocoumalol,Phenprocoumarol,Phenylpropylhydroxycumarinum,Falithrom,Liquamar,Marcoumar,Marcumar,Phenprogramma
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003278 Contraceptives, Oral, Hormonal Oral contraceptives which owe their effectiveness to hormonal preparations. Hormonal Oral Contraceptive,Hormonal Oral Contraceptive Agent,Contraceptive Agents, Estrogen,Contraceptive Agents, Oral, Hormonal,Hormonal Oral Contraceptive Agents,Oral Contraceptive Agents, Hormonal,Oral Contraceptives, Hormonal,Contraceptive, Hormonal Oral,Contraceptives, Hormonal Oral,Estrogen Contraceptive Agents,Hormonal Oral Contraceptives,Oral Contraceptive, Hormonal
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015110 4-Hydroxycoumarins Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants. 4 Hydroxycoumarins

Related Publications

H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
January 1983, Clinical pharmacokinetics,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
January 1986, Contraception,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
December 1990, American journal of obstetrics and gynecology,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
November 1971, Journal of reproduction and fertility,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
September 2016, Clinical pharmacology in drug development,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
August 1995, British journal of clinical pharmacology,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
July 1983, Contraception,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
January 1982, European journal of clinical pharmacology,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
February 1983, Contraception,
H Mönig, and C Baese, and H T Heidemann, and E E Ohnhaus, and H M Schulte
December 1990, American journal of obstetrics and gynecology,
Copied contents to your clipboard!